Citigroup
ALLO icon

Citigroup’s Allogene Therapeutics ALLO Stock Holding History

Citigroup’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$324K – 5763
2022
Q3 		$324K Buy
+30,000
New +$408K ﹤0.01% 3519

Other funds holding ALLO

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wildcat Capital Management
Wildcat Capital Management New York $174M AUM 46.5% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Harold Davidson & Associates
Harold Davidson & Associates Los Angeles, California $246M AUM 30.79% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
OpenArc Corporate Advisory
OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Citigroup's ALLO Position: Q3 2026 in Review

Citigroup reduced its Allogene Therapeutics (ALLO) stake by 40% in Q3 2026, selling an estimated $393K and leaving 308,864 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

Citigroup first reported a position in ALLO in Q4 2018 and has held it in 32 quarters since. The position peaked at $5.17M in Q2 2021. 52 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Citigroup held 308,864 shares of Allogene Therapeutics worth $494K as of Q3 2026.
  • Citigroup sold 206,635 Allogene Therapeutics shares in Q3 2026, an estimated $393K.
  • Allogene Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3762 holding.
  • Citigroup first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 32 quarters since.
  • Citigroup's Allogene Therapeutics position peaked at $5.17M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.